← Back to headlines
Summit Reports Positive Phase III Overall Survival Data for Ivonescimab
Summit (SMMT) reported positive Phase III overall survival data for its drug Ivonescimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC).
4 Jun, 09:05 — 4 Jun, 09:05
Sources
Showing 1 of 1 sources
